Following a successful 2025 kickoff in Illinois on March 25 and its third annual event in Massachusetts on June 4-5 featuring ...

As an innovative sleep product, the QuietLab stop snoring device is positioned as an ideal option for anyone seeking a ...

Nombre total de titres avec droits de vote: 37.435.640 (tous des actions ordinaires) Nombre total de droits de vote (= dénominateur): 37.435.640 (tous liés aux actions ordinaires) ...

The Russell 3000® Index is an equity index that tracks the performance of the largest 3,000 U.S. stocks by market capitalization. The Russell 2000® Index measures the performance of the 2,000 smallest ...

Total number of securities carrying voting rights: 37,435,640 (all ordinary shares) Total number of voting rights (= denominator): 37,435,640 (all relating to ordinary shares) ...

Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today the voting results from its annual general meeting of shareholders held virtually on June 27, 2025. All director ...

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.

High-resolution retinal imaging will be introduced by RetinalGenix as a value-added additional service at various locations in the near future. The integration of high-resolution imaging is expected ...

Sage Healthspan is currently available exclusively for iOS on Apple’s App Store. Users are encouraged to begin by uploading pre-existing lab results to generate immediate health insights. For more ...

“All of the FDA 510K approvals can be searched online. This is a big day for theranos,” says ElHosseiny. “Our goal is to bring advanced diagnostic technology to the public in a safe, transparent way.

PALM BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- In less than 24 hours after a meeting with the FDA, Ryan ElHosseiny, inventor and CEO of theranos, now calls on President Trump to pardon Elizabeth ...

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare ...